Literature DB >> 27277623

Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Remi Neviere1,2, Yichi Yu3,4, Lei Wang3,4, Frederic Tessier3, Eric Boulanger3.   

Abstract

Advanced glycation end products (AGEs) play an important role for the development and/or progression of cardiovascular diseases, mainly through induction of oxidative stress and inflammation. AGEs are a heterogeneous group of molecules formed by non-enzymatic reaction of reducing sugars with amino acids of proteins, lipids and nucleic acids. AGEs are mainly formed endogenously, while recent studies suggest that diet constitutes an important exogenous source of AGEs. The presence and accumulation of AGEs in various cardiac cell types affect extracellular and intracellular structure and function. AGEs contribute to a variety of microvascular and macrovascular complications through the formation of cross-links between molecules in the basement membrane of the extracellular matrix and by engaging the receptor for advanced glycation end products (RAGE). Activation of RAGE by AGEs causes up regulation of the transcription factor nuclear factor-κB and its target genes. of the RAGE engagement stimulates oxidative stress, evokes inflammatory and fibrotic reactions, which all contribute to the development and progression of devastating cardiovascular disorders. This review discusses potential targets of glycation in cardiac cells, and underlying mechanisms that lead to heart failure with special interest on AGE-induced mitochondrial dysfunction in the myocardium.

Entities:  

Keywords:  Advanced glycation end products; Cardiovascular; Mitochondria; Signaling pathways

Mesh:

Substances:

Year:  2016        PMID: 27277623     DOI: 10.1007/s10719-016-9679-x

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  103 in total

1.  Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans.

Authors:  Weijing Cai; Jaime Uribarri; Li Zhu; Xue Chen; Shobha Swamy; Zhengshan Zhao; Fabrizio Grosjean; Calogera Simonaro; George A Kuchel; Michal Schnaider-Beeri; Mark Woodward; Gary E Striker; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

2.  Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE.

Authors:  Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Lilian Grigorian-Shamagian; María Moure-González; Ana Seoane-Blanco; Alfonso Varela-Román; Ezequiel Alvarez; José R González-Juanatey
Journal:  Eur J Heart Fail       Date:  2010-08-03       Impact factor: 15.534

3.  A soluble receptor for advanced glycation end-products inhibits myocardial apoptosis induced by ischemia/reperfusion via the JAK2/STAT3 pathway.

Authors:  Xue Jiang; Cai-xia Guo; Xiang-jun Zeng; Hui-hua Li; Bu-xing Chen; Feng-he Du
Journal:  Apoptosis       Date:  2015-08       Impact factor: 4.677

4.  Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

Authors:  Jasper W L Hartog; Suzan Willemsen; Dirk J van Veldhuisen; Jan L Posma; Leen M van Wijk; Yoran M Hummel; Hans L Hillege; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2011-06-13       Impact factor: 15.534

5.  AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression.

Authors:  Eric Boulanger; Marie-Paule Wautier; Jean-Luc Wautier; Bernadette Boval; Yves Panis; Nicolas Wernert; Pierre-Marie Danze; Philippe Dequiedt
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

6.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

Review 7.  Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.

Authors:  Jasper W L Hartog; Adriaan A Voors; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2007-12       Impact factor: 15.534

8.  Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.

Authors:  Suzan Willemsen; Jasper W L Hartog; Yoran M Hummel; Jan L Posma; Leen M van Wijk; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2010-01-25       Impact factor: 15.534

Review 9.  Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.

Authors:  Suzan Willemsen; Jasper W L Hartog; M Rebecca Heiner-Fokkema; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

Review 10.  Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials.

Authors:  Rachel E Clarke; Aimee L Dordevic; Sih Min Tan; Lisa Ryan; Melinda T Coughlan
Journal:  Nutrients       Date:  2016-03-01       Impact factor: 5.717

View more
  10 in total

1.  Insights into the effects of N-glycosylation on the characteristics of the VC1 domain of the human receptor for advanced glycation end products (RAGE) secreted by Pichia pastoris.

Authors:  Genny Degani; Alberto Barbiroli; Paula Magnelli; Stefania Digiovanni; Alessandra Altomare; Giancarlo Aldini; Laura Popolo
Journal:  Glycoconj J       Date:  2019-01-05       Impact factor: 2.916

Review 2.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

3.  Skin Autofluorescence as a Predictor of First Heart Failure Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Takashi Hitsumoto
Journal:  Cardiol Res       Date:  2020-06-03

Review 4.  Effects of REDOX in Regulating and Treatment of Metabolic and Inflammatory Cardiovascular Diseases.

Authors:  Kai Wang; Yanhan Dong; Jing Liu; Lili Qian; Tao Wang; Xiangqian Gao; Kun Wang; Luyu Zhou
Journal:  Oxid Med Cell Longev       Date:  2020-11-17       Impact factor: 6.543

Review 5.  Role of Glycation in Type 2 Diabetes Mellitus and Its Prevention through Nymphaea Species.

Authors:  Nayab Ishrat; Hamda Khan; Om P S Patel; Abbas Ali Mahdi; Farina Mujeeb; Saheem Ahmad
Journal:  Biomed Res Int       Date:  2021-10-27       Impact factor: 3.411

6.  How Diabetes and Other Comorbidities of Elderly Patients and Their Treatment Influence Levels of Glycation Products.

Authors:  Aleksandra Kuzan; Emilia Królewicz; Irena Kustrzeba-Wójcicka; Karolina Lindner-Pawłowicz; Małgorzata Sobieszczańska
Journal:  Int J Environ Res Public Health       Date:  2022-06-20       Impact factor: 4.614

7.  Bushen Huoxue Attenuates Diabetes-Induced Cognitive Impairment by Improvement of Cerebral Microcirculation: Involvement of RhoA/ROCK/moesin and Src Signaling Pathways.

Authors:  Yuan Li; Quan Li; Chun-Shui Pan; Li Yan; Bai-He Hu; Yu-Ying Liu; Lei Yang; Ping Huang; Shao-Yang Zhao; Chuan-She Wang; Jing-Yu Fan; Xue-Mei Wang; Jing-Yan Han
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566

Review 8.  Immunomodulation by Processed Animal Feed: The Role of Maillard Reaction Products and Advanced Glycation End-Products (AGEs).

Authors:  Malgorzata Teodorowicz; Wouter H Hendriks; Harry J Wichers; Huub F J Savelkoul
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

Review 9.  Targeting Oxidative Stress and Mitochondrial Dysfunction in the Treatment of Impaired Wound Healing: A Systematic Review.

Authors:  Mariola Cano Sanchez; Steve Lancel; Eric Boulanger; Remi Neviere
Journal:  Antioxidants (Basel)       Date:  2018-07-24

10.  Integrative Role of Albumin: Evolutionary, Biochemical and Pathophysiological Aspects.

Authors:  D A Belinskaia; P A Voronina; N V Goncharov
Journal:  J Evol Biochem Physiol       Date:  2021-12-20       Impact factor: 0.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.